플루드로코르티손

용도

• Hypoadrenocorticism (Addison's disease)
• Hypoadrenocorticism (Addison's disease)

투여 방법

가능한 부작용

• Hypertension
• Oedema (including cerebral oedema)
• Hypokalaemia
• Hypercortisolism / Iatrogenic Cushing's syndrome (with long-term overdose)
• Polyuria/polydipsia (PU/PD)
• Clinical signs of hypercortisolism (with long-term overdose)

주의사항 및 금기

• No specific contraindications listed in the monograph, but use with caution in patients with congestive heart failure, severe hypertension, or renal disease.
• No specific contraindications available in the monograph, but generally contraindicated in patients with systemic fungal infections or known hypersensitivity.
• * Monitor **absolute sodium and potassium concentrations** (not just the Na:K ratio) 4-6 hours post-pill. * If dosing q24h, check Na/K concentrations pre-pill. * Supplemental doses of prednisolone may be required at times of metabolic or physical stress. * Some formulations require refrigeration. * **Clinical Pearl:** Dose requirements often increase over the first 6-18 months of therapy as residual adrenal function ceases.

약물 상호작용

• Amphotericin B: Increased risk of severe hypokalaemia
• Furosemide: Increased risk of hypokalaemia due to additive potassium-depleting effects
• Thiazide diuretics: Increased risk of hypokalaemia due to additive potassium-depleting effects

자주 묻는 질문